START FREE TRIAL
Home Consumer Discretionary DexCom, Inc.

DexCom, Inc.

$19.00

SKU: DXCM-1 Category:

Description

Dexcom’s $1.34 Billion Revenue Quarter: Can CGM Adoption Sustain Double-Digit Growth?

 

Dexcom, Inc. reported third quarter 2026 revenue of $1.34 billion, reflecting an 11% year-over-year increase on both a reported and organic basis. U.S. revenue grew 14% to $970 million, driven by market share gains across multiple customer segments, particularly among type 2 diabetes patients not on insulin. International revenue rose 5% to $375 million, though tempered by lapping previous reimbursement wins from 2025, with management anticipating normalization to higher organic growth in 2027. The company’s active customer base experienced upper teen growth, supported by record new patient starts and focused retention efforts. Gross margin improved by approximately 380 basis points to 65.1%, attributed to manufacturing efficiencies, freight and quality management improvements, and the continued ramp of the G7 15 Day system in the U.S. Operating expenses increased to $535.8 million from $468.4 million in the prior year quarter due to investments such as the ramp-up of the Ireland manufacturing facility.